Journal of Clinical Oncology, Vol 25, No 10 (April 1), 2007: pp. 1169-1175
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.08.2933
Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy?
Jeffrey H. Silber,
Paul R. Rosenbaum,
Daniel Polsky,
Richard N. Ross,
Orit Even-Shoshan,
J. Sanford Schwartz,
Katrina A. Armstrong,
Thomas C. Randall
From the Center for Outcomes Research, The Children's Hospital of Philadelphia; Department of Pediatrics, Division of Pediatric Oncology and Department of Anesthesiology and Critical Care, Division of General Internal Medicine, and Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania School of Medicine; The Leonard Davis Institute of Health Economics, the University of Pennsylvania; and the Department of Statistics, The Wharton School, Philadelphia, PA
Address reprint requests to Jeffrey H. Silber, MD, PhD, The Center for Outcomes Research, The Children's Hospital of Philadelphia, 3535 Market St, Ste 1029, Philadelphia, PA 19104; e-mail: silber{at}email.chop.edu
Purpose Chemotherapy for ovarian cancer is usually administered by medical oncologists (MOs) or gynecologic oncologists (GOs). GOs perform a broad spectrum of surgical and medical activities while managing a limited number of diseases; MOs specialize in the administration of chemotherapy but manage a broad array of diseases. We asked whether survival, treatment, and toxicity differed according to the type of specialist providing the chemotherapy after surgery.
Patients and Methods Using Surveillance, Epidemiology, and End Results (SEER) -Medicare data for patients  65 years old from 1991 through 2001 from eight SEER sites, we identified 344 patients with ovarian cancer who were treated with chemotherapy by a GO after surgery. Using optimal matching and propensity scores based on 36 characteristics, we matched these patients to 344 similar patients who were operated on and staged by the same type of surgeon but who received chemotherapy from an MO.
Results MOs administered chemotherapy over more weeks than did the GOs (16.5 v 12.1 weeks, respectively; P < .0023), and MO patients had substantially more weeks that included chemotherapy-associated adverse events than GO patients (16.2 v 8.9 weeks, respectively; P < .0001). However, there was no difference in 5-year survival rate between the GO and MO groups (35% v 34%, respectively; P = .45).
Conclusion GO- and MO-treated patients who were closely matched on prognostic characteristics experienced very different rates of chemotherapy-associated adverse events and very different chemotherapy treatment styles by specialty type; however, their survival was virtually identical.
Supported by Grant No. R01-CA095664 (J.H.S.) from the National Cancer Institute and Grant No. SES-0345113 (P.R.R.) from the National Science Foundation.
Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Gynecologic Oncology or Medical Oncology: What's in a Name?
Stephen A. Cannistra
JCO 2007 25: 1157-1159
[Full Text]
Related Correspondence
- More Than a Name
Stephanie V. Blank and John P. Curtin
JCO 2007 25: 3551
[Full Text]
- Chemotherapy Administration for Ovarian Cancer by Gynecologic Oncologists and Medical Oncologists
Andrew Berchuck
JCO 2007 25: 3552
[Full Text]
- Type of Oncology Specialist and Treatment-Related Outcomes in Ovarian Cancer
Mark A. Hoffman and Uzma Iqbal
JCO 2007 25: 3553
[Full Text]
- Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy?
Maurie Markman
JCO 2007 25: 3554
[Full Text]
- Ovarian Cancer and the Battle of the Specialists
William P. McGuire
JCO 2007 25: 3554-3555
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
S. T. Tang, S.-C. Wu, Y.-N. Hung, J.-S. Chen, E.-W. Huang, and T.-W. Liu
Determinants of Aggressive End-of-Life Care for Taiwanese Cancer Decedents, 2001 to 2006
J. Clin. Oncol.,
September 20, 2009;
27(27):
4613 - 4618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Schrag
Enhancing Cancer Registry Data to Promote Rational Health System Design
J Natl Cancer Inst,
March 19, 2008;
100(6):
378 - 379.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Blank and J. P. Curtin
More Than a Name
J. Clin. Oncol.,
August 10, 2007;
25(23):
3551 - 3551.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Berchuck
Chemotherapy Administration for Ovarian Cancer by Gynecologic Oncologists and Medical Oncologists
J. Clin. Oncol.,
August 10, 2007;
25(23):
3552 - 3552.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hoffman and U. Iqbal
Type of Oncology Specialist and Treatment-Related Outcomes in Ovarian Cancer
J. Clin. Oncol.,
August 10, 2007;
25(23):
3553 - 3553.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman
Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy?
J. Clin. Oncol.,
August 10, 2007;
25(23):
3554 - 3554.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Silber and P. R. Rosenbaum
In Reply
J. Clin. Oncol.,
August 10, 2007;
25(23):
3555 - 3557.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Cannistra
In Reply
J. Clin. Oncol.,
August 10, 2007;
25(23):
3557 - 3558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. McGuire
Ovarian Cancer and the Battle of the Specialists
J. Clin. Oncol.,
August 10, 2007;
25(23):
3554 - 3555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Do Ovarian Cancer Outcomes Vary by Type of Specialist Providing Chemotherapy?
Journal Watch Women's Health,
May 3, 2007;
2007(503):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
S. A. Cannistra
Gynecologic Oncology or Medical Oncology: What's in a Name?
J. Clin. Oncol.,
April 1, 2007;
25(10):
1157 - 1159.
[Full Text]
[PDF]
|
|
|
|
